Table 2.

Factors associated with follow-up termination

FactorUnivariateMultivariate
HR (95% CI)PHR (95% CI)P
Patient age (up to 16 y after HCT), y*
 <150.65 (0.60-0.70)<.0010.60 (0.56-0.66)<.001
 15-291.00 (reference)1.00 (reference)
 30-390.86 (0.79-0.94).0010.89 (0.82-0.97).011
 ≥400.74 (0.68-0.79)<.0010.79 (0.73-0.86)<.001
Patient age (beyond 16 y after HCT), y*
 <150.79 (0.62-1.01).0620.77 (0.60-0.99).04
 15-291.00 (reference)1.00 (reference)
 30-390.89 (0.64-1.24).490.87 (0.62-1.22).43
 ≥400.66 (0.44-0.99).050.66 (0.44-1.00).05
Patient sex
 Male1.00 (reference)1.00 (reference)
 Female1.11 (1.05-1.18)<.0011.12 (1.06-1.19)<.001
Disease
 Standard-risk malignancy1.00 (reference)1.00 (reference)
 High-risk malignancy0.84 (0.79-0.90)<.0010.86 (0.81-0.92)<.001
 Nonmalignant disease1.21 (1.12-1.30)<.0011.14 (1.06-1.24).001
Conditioning
 Myeloablative1.00 (reference)
 Reduced intensity0.97 (0.91-1.04).40
 Unknown intensity1.11 (1.03-1.20).005
Donor type
 Related BM1.00 (reference)1.00 (reference)
 Related PBSC0.92 (0.84-1.01).0811.05 (0.95-1.16).37
 Unrelated BM1.13 (1.06-1.20)<.0011.19 (1.11-1.27)<.001
 Unrelated PBSC0.52 (0.08-3.47).500.56 (0.09-3.33).53
 Cord blood0.82 (0.64-1.05).110.88 (0.68-1.13).31
 Haploidentical related0.94 (0.85-1.03).190.98 (0.88-1.09).73
HLA matching
 Match1.00 (reference)
 Mismatch1.00 (0.94-1.07).89
Year of transplantation
 1974-19990.96 (0.90-1.02).160.92 (0.86-0.99).017
 2000-20051.00 (reference)1.00 (reference)
 2006-20130.86 (0.80-0.93)<.0010.86 (0.80-0.93)<.001
Maximum grade of acute GVHD
 Grade 0-I1.00 (reference)
 Grade II0.91 (0.85-0.97).005
 Grade III-IV0.84 (0.76-0.93).001
Chronic GVHD before 2 y
 None1.00 (reference)1.00 (reference)
 Limited0.82 (0.77-0.88)<.0010.82 (0.77-0.89)<.001
 Extensive0.67 (0.63-0.72)<.0010.67 (0.62-0.72)<.001
  • BM, bone marrow; PBSC, mobilized blood cells.

  • * Separate analyses were performed before and after 16 years because of the violation of proportional assumption.

  • Cord blood and haploidentical transplantation were excluded.